We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+18.8%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.68B
AUM Growth
+$421M
Cap. Flow
+$308M
Cap. Flow %
11.53%
Top 10 Hldgs %
68.02%
Holding
83
New
12
Increased
16
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$68.6M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$52.4M
3
RLAY icon
Relay Therapeutics
RLAY
+$34.9M
4
RCUS icon
Arcus Biosciences
RCUS
+$32.5M
5
JANX icon
Janux Therapeutics
JANX
+$31.4M

Top Sells

Rank Stock Value
1
ELDN icon
Eledon Pharmaceuticals
ELDN
+$11.9M
2
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$10.5M
3
NGNE icon
Neurogene
NGNE
+$8.45M
4
ACIU icon
AC Immune
ACIU
+$6.91M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Financials 0.6%
3 Miscellaneous 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$580M 21.68%
11,284,280
+250,000
+2% +$7.8M
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$227M 8.48%
3,951,566
+952,251
+32% +$52.4M
ANAB icon
3
AnaptysBio
ANAB
$1.67B
$195M 7.29%
7,521,024
+369,400
+5% +$8.85M
XNCR icon
4
Xencor
XNCR
$1.94B
$169M 6.32%
4,906,106
+5,800
+0.1% +$230K
RLAY icon
5
Relay Therapeutics
RLAY
$4.11B
$164M 6.14%
4,487,776
+1,058,413
+31% +$34.9M
NUVB icon
6
Nuvation Bio
NUVB
$2.34B
$128M 4.77%
13,711,517
+464,500
+4% +$5.3M
STTK icon
7
Shattuck Labs
STTK
$707M
$96.2M 3.6%
3,318,410
+860,151
+35% +$25.1M
RCUS icon
8
Arcus Biosciences
RCUS
$3.72B
$91.6M 3.42%
3,335,247
+1,139,355
+52% +$32.5M
ALEC icon
9
Alector
ALEC
$261M
$88.4M 3.3%
4,242,634
+3,640,034
+604% +$68.6M
SPRY icon
10
ARS Pharmaceuticals
SPRY
$586M
$80.9M 3.02%
2,618,036
+84,401
+3% +$2.71M
KURA icon
11
Kura Oncology
KURA
$1.13B
$77.7M 2.9%
3,724,437
+31,800
+0.9% +$789K
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$75M 2.8%
464,298
– –
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.37B
$54.7M 2.04%
3,092,218
– –
NRIX icon
14
Nurix Therapeutics
NRIX
$2.72B
$52.2M 1.95%
1,967,950
-51,069
-3% -$1.5M
RNAM
15
DELISTED
Avidity Biosciences
RNAM
$52M 1.94%
2,103,950
– –
JANX icon
16
Janux Therapeutics
JANX
$1.1B
$35.2M 1.32%
+1,411,975
New +$31.4M
SLDB icon
17
Solid Biosciences
SLDB
$1.05B
$33.7M 1.26%
613,513
– –
GRTS
18
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$31.2M 1.17%
3,421,287
– –
TBIO
19
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$28.9M 1.08%
1,048,976
+452,076
+76% +$8.88M
ITOS
20
DELISTED
iTeos Therapeutics
ITOS
$26.6M 0.99%
1,035,864
+775,864
+298% +$18.5M
EWTX icon
21
Edgewise Therapeutics
EWTX
$4.64B
$26.1M 0.98%
1,224,175
– –
KYMR icon
22
Kymera Therapeutics
KYMR
$9.82B
$25.2M 0.94%
519,416
+419,416
+419% +$18.2M
DSGN icon
23
Design Therapeutics
DSGN
$946M
$25.1M 0.94%
1,260,019
+122,079
+11% +$3.08M
AKUS
24
DELISTED
Akouos Inc
AKUS
$24.8M 0.93%
1,975,984
– –
ARVN icon
25
Arvinas
ARVN
$600M
$24.8M 0.93%
321,724
+3,020
+0.9% +$210K
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2021 Portfolio in Review

As of Q2 2021, EcoR1 Capital held 83 positions worth $2.68B, up 19% from $2.25B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $308M of net new capital in Q2 2021, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Janux Therapeutics: 1,411,975 shares worth $35.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Neurogene, an estimated $8.45M trimmed.

  • EcoR1 Capital's largest Q2 2021 buy was Janux Therapeutics: 1,411,975 shares worth $35.2M.
  • EcoR1 Capital added most to Alector in Q2 2021, an estimated $68.6M increase.
  • EcoR1 Capital's biggest Q2 2021 reduction was Neurogene, cutting an estimated $8.45M.
  • EcoR1 Capital fully exited Eledon Pharmaceuticals in Q2 2021, selling an estimated $11.9M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.68B portfolio in Q2 2021.
  • EcoR1 Capital opened 12 new positions and closed 11 in Q2 2021.
  • EcoR1 Capital's portfolio value rose 19% quarter-over-quarter to $2.68B.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.